June 5, 2022 11:07 AM EDT

#ASCO22: In yet another stinging setback, Pfizer’s blockbuster CDK 4/6 fails its latest test on survival. But can Novartis and Eli Lilly benefit?

In the latest in a series of big clinical setbacks, Pfizer reported at ASCO that its closely watched PALOMA-2 Phase III study of Ibrance combined …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#AS­CO22: In yet an­oth­er sting­ing set­back, Pfiz­er’s block­buster CDK 4/6 fails its lat­est test on sur­vival. But can No­var­tis and Eli Lil­ly ben­e­fit?